Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial. (linkinghub.elsevier.com)

Authors: Davids MS … Wierda WG Journal: The Lancet Published: 2026-07-09 DOI: https://doi.org/10.1016/S0140-6736(26)01204-3